WO2026002967A1 - Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associées - Google Patents
Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associéesInfo
- Publication number
- WO2026002967A1 WO2026002967A1 PCT/EP2025/067711 EP2025067711W WO2026002967A1 WO 2026002967 A1 WO2026002967 A1 WO 2026002967A1 EP 2025067711 W EP2025067711 W EP 2025067711W WO 2026002967 A1 WO2026002967 A1 WO 2026002967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- use according
- leoligin
- calcium
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (I) qui agissent en tant que bloqueur des canaux calciques, destinés à être utilisés dans la prévention et/ou le traitement de maladies associées à un dysfonctionnement des canaux calciques et/ou un déséquilibre dans l'homéostasie calcique intracellulaire, telles que l'hypertension, la maladie de Raynaud, la migraine, la prophylaxie de la migraine, les infections virales, l'angine de poitrine, les arythmies, l'hémorragie sous-arachnoïdienne, la cardiomyopathie hypertrophique, le spasme œsophagien et l'hypertension pulmonaire, ainsi qu'une composition et une composition pharmaceutique comprenant lesdits composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP24183982 | 2024-06-24 | ||
| EP24183982.8 | 2024-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2026002967A1 true WO2026002967A1 (fr) | 2026-01-02 |
Family
ID=91664603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2025/067711 Pending WO2026002967A1 (fr) | 2024-06-24 | 2025-06-24 | Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associées |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2026002967A1 (fr) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792207A1 (de) | 1967-08-08 | 1971-11-04 | Fisons Pharmaceuticals Ltd | Pharmazeutische Praeparate |
| EP0229644B1 (fr) | 1986-01-10 | 1992-09-30 | Warner-Lambert Company | Procédé d'utilisation du diltiazem, verapamil ou nifedipine agissant dans le traitement de l'apoplexie |
| US20130053438A1 (en) | 2010-01-19 | 2013-02-28 | Universitat Innsbruck | Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity |
| US20140371306A1 (en) | 2008-07-18 | 2014-12-18 | Universität Innsbruck | Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| US20170157301A1 (en) | 2014-06-24 | 2017-06-08 | Technische Universitäet Wien | Leoligin derivatives as smooth muscle cell proliferation inhibitors |
| WO2022043481A1 (fr) | 2020-08-28 | 2022-03-03 | Universität Linz | Utilisation de léoligine dans la prévention de lésions tissulaires |
| WO2023104159A1 (fr) * | 2021-12-09 | 2023-06-15 | Xie Mingqi | Inhibiteur des canaux calciques et procédé de criblage associé |
-
2025
- 2025-06-24 WO PCT/EP2025/067711 patent/WO2026002967A1/fr active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792207A1 (de) | 1967-08-08 | 1971-11-04 | Fisons Pharmaceuticals Ltd | Pharmazeutische Praeparate |
| EP0229644B1 (fr) | 1986-01-10 | 1992-09-30 | Warner-Lambert Company | Procédé d'utilisation du diltiazem, verapamil ou nifedipine agissant dans le traitement de l'apoplexie |
| US20140371306A1 (en) | 2008-07-18 | 2014-12-18 | Universität Innsbruck | Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| US20130053438A1 (en) | 2010-01-19 | 2013-02-28 | Universitat Innsbruck | Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity |
| US20170157301A1 (en) | 2014-06-24 | 2017-06-08 | Technische Universitäet Wien | Leoligin derivatives as smooth muscle cell proliferation inhibitors |
| WO2022043481A1 (fr) | 2020-08-28 | 2022-03-03 | Universität Linz | Utilisation de léoligine dans la prévention de lésions tissulaires |
| WO2023104159A1 (fr) * | 2021-12-09 | 2023-06-15 | Xie Mingqi | Inhibiteur des canaux calciques et procédé de criblage associé |
Non-Patent Citations (13)
| Title |
|---|
| "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING |
| DYLAN COOPERMANJARI DIMRI: "Biochemistry, Calcium Channels", 2023, STATPEARLS PUBLISHING |
| GODFRAIND, T.: "Calcium-channel modulators for cardiovascular disease", EXPERT OPINION ON EMERGING DRUGS, vol. 11, no. 1, 2006, pages 49 - 73 |
| GOMMANS, 1.VLAK, M. H.DE HAAN, A.VAN ENGELEN, B.: "Calciumregulation and muscle disease", JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, vol. 23, no. 1, 2002, pages 59 - 63 |
| KISTAMAS, K., VERESS, R., HORVATH, B., BANYASZ, T., NANASI, P. P., & EISNER, D.: "Calcium handling defects and cardiac arrhythmia syndromes", FRONTIERS IN PHARMACOLOGY, vol. 11, 2020 |
| LI HONG HU, J. NAT. PROD., vol. 68, 2005, pages 342 - 8 |
| LINDER ET AL., CHEM. SCI., vol. 10, no. 22, 2019, pages 5815 - 5820 |
| LINDER, T.GEYRHOFER, S.PAPAPLIOURA, E.WANG, L.ATANASOV, A. G.STUPPNER, H.DIRSCH, V. M.SCHNÜRCH, M.MIHOVILOVIC, M. D.: "Design and synthesis of a compound library exploiting 5-Methoxyleoligin as potential cholesterol efflux promoter", MOLECULES, vol. 25, no. 3, 2020, pages 662, XP093228864, DOI: 10.3390/molecules25030662 |
| MONTEITH, G. R.DAVIS, F. M.ROBERTS-THOMSON, S. J.: "Calcium channels and pumps in Cancer: Changes and consequences", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 38, 2012, pages 31666 - 31673 |
| NAM, J. H.KIRN, W. K.: "The Role ofTRP Channels in Allergie Inflammation and its Clinical Relevance", CURRENT MEDICINAL CHEMISTRY, vol. 27, no. 9, 2020, pages 1446 - 1468 |
| REISINGER, U.SCHWAIGER, S.ZELLER, 1.MEΒNER, B.STIGLER, R.WIEDEMANN, D.MAYR, T.SEGER, C.SCHACHNER, T.DIRSCH, V. M.: "Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts", CARDIOVASCULAR RESEARCH, vol. 82, no. 3, 2009, pages 542 - 549, XP007918229, DOI: 10.1093/cvr/cvp059 |
| SHAH, K.SEELEY, S. L.SCHULZ, C.FISHER, J. L.RAO, S. G.: "Calcium channels in the heart: Disease states and drugs", CELLS, vol. 11, no. 6, 2022, pages 943 |
| WANG, L.LADURNER, A.LATKOLIK, S.SCHWAIGER, S.LINDER, T.HOSEK, J.PALME, V.SCHILCHER, N.POLANSKY, O.HEISS, E.H.: "Leoligin, the Major Lignan from Edelweiss (Leontopodium nivale subsp. alpinum), Promotes Cholesterol Efflux from THP-1 Macrophages", JOURNAL OF NATURAL PRODUCTS, vol. 79, no. 6, 2016, pages 1651 - 1657 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203936B2 (en) | The use of isosteviol in the manufacture of medicament for treatment of cardiac fibrosis remodeling | |
| USRE49035E1 (en) | Traditional Chinese medicine composition, and preparation and application thereof | |
| Li et al. | A chlorogenic acid-phospholipid complex ameliorates post-myocardial infarction inflammatory response mediated by mitochondrial reactive oxygen species in SAMP8 mice | |
| EP3020407A1 (fr) | Composition de médecine chinoise traditionnelle, procédé de préparation et application associés | |
| CN114728919B (zh) | MrgprX2拮抗剂及其用途 | |
| EP3851101A1 (fr) | Acides tétrahydrocannabinol-11-oïques ultrapurs | |
| IL298060A (en) | Uses and formulations of cannabinoids | |
| WO2014180238A1 (fr) | Composition médicinale anti-anoxie et son application | |
| JP2003535888A (ja) | 食後のトリグリセリドに富んだリポタンパク質粒子（ｐｐｔｒｌ）の数を低下させるための、ミクロソームのトリグリセリド輸送タンパク質（ｍｔｐ）インヒビターの使用 | |
| EP3074045B1 (fr) | Composition aqueuse pulvérisable comprenant du trinitrate de glycéryle | |
| WO2021196659A1 (fr) | Liposome de composé de polyéther glycosylique, procédé de préparation de celui-ci et médicament à base de celui-ci | |
| JP2002534379A (ja) | 新規なブレチリウム組成物およびキットならびに心血管症状の予防および治療におけるそれらの使用 | |
| WO2026002967A1 (fr) | Léoligine et ses dérivés en tant que bloqueurs des canaux calciques pour la prévention et/ou le traitement de maladies associées | |
| US20230310363A1 (en) | Use of leoligin in the prevention of tissue damage | |
| EP4623908A1 (fr) | Utilisation d'un composé de gallate de (-)-épigallocatéchine | |
| US20230181485A1 (en) | Uses and Formulations of Cannabinoids | |
| AU2017370956B2 (en) | Powder solid compositions, process for their preparation, formulations and use thereof | |
| WO2017011445A1 (fr) | Carbonitriles hétéroaryles pour le traitement de maladie | |
| CN119770568A (zh) | 一种中药组合物、药物制剂及用途 | |
| KR20210083485A (ko) | 알피늄이소플라빈 가용화 조성물 및 이의 용도 | |
| JPWO2006107059A1 (ja) | 腎灌流障害用薬 |